Cognition AI Inc. is in early talks to raise a new round of funding that would more than double its valuation to $25 billion, ...
Positive Discussion on Path Forward for Registrational Program - PURCHASE, N.Y., May 21, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a ...
MedPage Today on MSN
Study Questions Methods Used in Alzheimer's Drug Analysis
Quantile aggregation may lead to overstated claims about amyloid-cognition relationships ...
Cognition Therapeutics, led by CEO Lisa Ricciardi, is on a mission to change the course of neurodegenerative diseases. | ...
Forbes contributors publish independent expert analyses and insights. Dr. Lance B. Eliot is a world-renowned AI scientist and consultant. In today’s column, I examine the ongoing pursuit by psychology ...
Millions of people are diagnosed with Alzheimer's disease each year, comprising 60% to 70% of dementia cases worldwide. While cognitive impairment and structural brain changes are indicative of ...
Company’s memory precision assessment, “PREMAZ,” detects subtle cognitive changes years before traditional tests, ...
Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that a second philanthropic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results